3D MEDICINES
No. 3 and No. 5, Laiyang Road
Qingdao 266000
China
https://www.3d-medicines.com
版塊: Healthcare
行業: Biotechnology
全職員工: 198
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Zhaolong Gong M.D., Ph.D. | Key Founder, CEO & Executive Chairman | 1.95M | 無 | 1965 |
| Ms. Jing Zhang | Chief Financial Officer | 無 | 無 | 1974 |
| Dr. Shen Xiao | Chief Strategy Officer & Chief Medical Officer | 無 | 無 | 1966 |
| Ms. Fang Xia | Head of Regulatory Affairs, VP & Joint Company Secretary | 無 | 無 | 1981 |
| Ms. Ching Yi Li | Joint Company Secretary | 無 | 無 | 無 |
描述
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
公司管治
截至 無 止，3D MEDICINES 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
